Biliary Atresia

Biliary atresia, also known as "extrahepatic ductopenia" and "progressive obliterative cholangiopathy" is a congenital or acquired disease of the liver and one of the principal forms of chronic rejection of a transplanted liver allograft. As a birth defect in newborn infants, it has an occurrence of 1/10,000 to 1/15,000 cases in live births in the United States. In the congenital form, the common bile duct between the liver and the small intestine is blocked or absent. The acquired type most often occurs in the setting of autoimmune disease, and is one of the principal forms of chronic rejection of a transplanted liver allograft.

Infants and children with biliary atresia have progressive cholestasis with all the usual concomitant features: pruritus, malabsorption with growth retardation, fat-soluble vitamin deficiencies, hyperlipidemia, and eventually cirrhosis with portal hypertension. If unrecognized, the condition leads to liver failure -- but not kernicterus, as the liver is still able to conjugate bilirubin, and conjugated bilirubin is unable to cross the blood-brain barrier. The cause of the condition is unknown. The only effective treatments are certain surgeries such as the kasai procedure, or liver transplantation.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Plant compounds give '1-2' punch to colon cancer

The combination of two plant compounds that have medicinal properties - curcumin and silymarin - holds promise in treating colon cancer, according Saint Louis University research published in the June 23 issue of the Journal ...

For whom the births (and worms) toll

Human childbirth is not only unpleasant, it's also assumed to take a toll on women's health, even while women have a greater life expectancy. A new study led by UC Santa Barbara researchers, however, finds that indigenous ...

Chinese team to pioneer first human CRISPR trial

(Medical Xpress)—A team of researchers at Sichuan University's West China Hospital has announced plans to begin a clinical trial where cells modified using the CRISPR gene editing technique will be used on human beings ...